How not to miss autoinflammatory diseases masquerading as urticaria

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 12, 2012, Pages 1465-1474

  Krause, K ^a   Grattan, C E ^b   Bindslev Jensen, C ^c   Gattorno, M ^d   Kallinich, T ^a   De Koning, H D ^e   Lachmann, H J ^f   Lipsker, D ^g   Navarini, A A ^h   Simon, A ^e   Traidl Hoffmann, C ⁱ   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d G GASLINI INSTITUTE   (Italy)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

autoinflammation; cryopyrin associated periodic syndrome; interleukin 1; Schnitzler's syndrome; urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; CRYOPYRIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR RECEPTOR;

AMYLOIDOSIS; ARTHRALGIA; ARTHRITIS; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; EYE INFLAMMATION; FATIGUE; HEADACHE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEVALONATE KINASE DEFICIENCY; PRIORITY JOURNAL; REVIEW; SCHNITZLER SYNDROME; SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS; URTICARIA; WELLS SYNDROME;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; EXANTHEMA; HUMANS; INFLAMMATION; URTICARIA;

EID: 84869507373     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12030     Document Type: Review

References (56)

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010; 65: 290-295.
3. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
4. Peroni A, Colato C, Zanoni G, Girolomoni G,. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases J Am Acad Dermatol 2010; 62: 557-570; quiz 571-572.
5. Van der Hilst JC, Simon A, Drenth JP,. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5: 87-98.
6. Stych B, Dobrovolny D,. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008; 24: 1577-1582.
7. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008; 87: 301-310.
8. Aksentijevich I, C DP, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56: 1273-1285.
9. Petrilli V, Dostert C, Muruve DA, Tschopp J,. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-622.
10. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J,. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-325.
11. Nakamura Y, Kambe N, Saito M, Nishikomori R, Kim YG, Murakami M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 2009; 206: 1037-1046.
12. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-592.
13. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-2452.
14. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-2425.
15. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095-2102.
16. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011; 63: 840-849.
17. Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58: 2432-2442.
18. Schnitzler L,. Lésions urticariennes chroniques permanentes (érythème pétaloïde?). J Dermatol Angers 1972;Cas cliniques No 46 B:Abstract 46.
19. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E,. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001; 80: 37-44.
20. de Koning HD, Bodar EJ, van der Meer JW, Simon A,. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-148.
21. Lipsker D,. The Schnitzler syndrome. Orphanet J Rare Dis 2010; 5: 38.
22. Asli B, Brouet JC, Fermand JP,. Spontaneous remission of Schnitzler syndrome. Ann Allergy Asthma Immunol 2011; 107: 87-88.
23. Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F, et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009; 48: 1304-1308.
24. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL,. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005; 52: 2226-2227.
25. Schneider SW, Gaubitz M, Luger TA, Bonsmann G,. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 2007; 56 (5 Suppl): S120-S122.
26. Dybowski F, Sepp N, Bergerhausen HJ, Braun J,. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 2008; 26: 354-357.
27. de Koning HD, Schalkwijk J, van der Meer JW, Simon A,. Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011; 128: 1352-1354.
28. Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-950.
29. Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008; 105: 1614-1619.
30. Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R, et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011; 63: 830-839.
31. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-430.
32. Yamamoto T,. Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic values. Rheumatol Int 2012; 32: 2233-2237.
33. Riera E, Olive A, Narvaez J, Holgado S, Santo P, Mateo L, et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol 2011; 29: 331-336.
34. Efthimiou P, Kontzias A, Ward CM, Ogden NS,. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007; 3: 328-335.
35. Prakken B, Albani S, Martini A,. Juvenile idiopathic arthritis. Lancet 2011; 377: 2138-2149.
36. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-555.
37. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-567.
38. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-754.
39. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
40. Frosch M, Roth J,. New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment. Rheumatology (Oxford) 2008; 47: 121-125.
41. Stoffels M, Simon A,. Hyper-IgD syndrome or mevalonate kinase deficiency. Curr Opin Rheumatol 2011; 23: 419-423.
42. Rezaei N,. TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder. Clin Rheumatol 2006; 25: 773-777.
43. Weller K, Viehmann K, Brautigam M, Krause K, Siebenhaar F, Zuberbier T, et al. Cost-intensive, time-consuming, problematical? How physicians in private practice experience the care of urticaria patients J Dtsch Dermatol Ges 2012; 10: 341-347.
44. Kieffer C, Cribier B, Lipsker D,. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23-31.
45. Krause K, Feist E, Fiene M, Kallinich T, Maurer M,. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012; 129: 848-850.
46. Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63: 1151-1155.
47. Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D,. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010; 69: 677-682.
48. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371.
49. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-1036.
50. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-3348.
51. Ait-Idir D, Khilan A, Djerdjouri B, El-Shanti H,. Spectrum of mutations and carrier frequency of familial Mediterranean fever gene in the Algerian population. Rheumatology (Oxford) 2011; 50: 2306-2310.
52. Gattorno M, Sormani MP, D'Osualdo A, Pelagatti MA, Caroli F, Federici S, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58: 1823-1832.
53. Hoffman HM, Wanderer AA, Broide DH,. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001; 108: 615-620.
54. Gandhi C, Healy C, Wanderer AA, Hoffman HM,. Familial atypical cold urticaria: description of a new hereditary disease. J Allergy Clin Immunol 2009; 124: 1245-1250.
55. Wanderer AA, Hoffman HM,. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004; 24: 259-286, vii.
56. Kivity S, Schwartz Y, Wolf R, Topilsky M,. Systemic cold-induced urticaria-clinical and laboratory characterization. J Allergy Clin Immunol 1990; 85 (1 Pt 1): 52-54.